Neuroimaging Core

神经影像核心

基本信息

批准号：
10264435
负责人：
SHANNON L RISACHER
金额：
$ 35.66万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10264435
关键词：
3-Dimensional Academia Aging Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease related dementia Amyloid Award Biological Markers Brain imaging Cataloging Clinical Clinical Research Clinical assessments Collaborations Communities Data Data Set Degenerative Disorder Dementia Development Diffusion Discipline Disease Drug Industry Early Diagnosis Elderly Ensure Faculty Family Fostering Functional Magnetic Resonance Imaging Funding Genetic Genetic Markers Genetic study Goals Grant Healthcare Industry Human Hybrids Image Image Analysis Impaired cognition Indiana Individual Industry Inherited International Magnetic Resonance Imaging Measures Methodology Methods Molecular Mus Nerve Degeneration Neuropsychology Neurosciences Research Participant Pathologic Perfusion Phase Pilot Projects Positron-Emission Tomography Postdoctoral Fellow Productivity Protocols documentation Quality Control Research Research Personnel Resolution Resources Rest Rotation Sampling Scanning Schools Scientist Spin Labels Standardization Structure Techniques Therapeutic Effect Therapeutic Studies Tracer Training Translational Research Validation Vision animal imaging base causal variant cognitive testing connectome cooperative study data management design disease mechanisms study drug discovery education research experience genetic analysis imaging biomarker imaging genetics imaging modality improved in vivo metabolomics mild cognitive impairment multimodality neuroimaging neuropathology new therapeutic target outreach perfusion imaging pre-clinical prevent prisma programs protocol development recruit statistics symposium tau Proteins tau aggregation tool undergraduate student

项目摘要

Project Summary – Neuroimaging Core (NIC) The NIC of the IADRC will serve as a regional and national resource for the aging and neurodegeneration research community by providing access to, and collaborative support for, the application of advanced neuroimaging in clinical and translational research. The NIC has been productive in developing and implementing cutting-edge protocols and techniques in neuroimaging and imaging genetics analysis, collaborating with NIA-funded initiatives (e.g., ADNI, DIAN, ADGC, etc.), and in providing training in neuroimaging and imaging genetics to scientists of all levels and disciplines. In this application, the NIC will pursue the following specific aims: (1) Support funded research in the IADRC, IU Center for Aging Research, and related programs that currently employ or could benefit from advanced neuroimaging; (2) Provide standardized, state-of-the-art neuroimaging acquisition and analysis protocols; (3) Expand transdisciplinary regional neuroscience research using advanced neuroimaging tools to study disease mechanisms and treatments for neurodegeneration; (4) Support and collaborate with major national and international AD-related research consortia using neuroimaging and genetics methods; (5) Provide transdisciplinary educational opportunities in neuroimaging and genetics of AD and other degenerative disorders for basic and clinical scientists at all levels from undergraduates to post-doctoral fellows and faculty, as well as dissemination of neuroimaging results to the community. The NIC, working closely with the Clinical Core, will perform state-of- the-art multimodal MRI (Siemens Prisma 3T: high resolution structural, 3D pCASL perfusion, multiband resting- state and task-based fMRI, and hybrid diffusion and DTI optimized for structural and functional connectome analysis) on all eligible IADRC participants, as well as amyloid and/or tau PET on >200 IADRC participants. Participants in preclinical or early symptomatic phases (e.g., subjective cognitive decline or mild cognitive impairment), late-onset AD, and individuals from families with mutations causal for dementias will be prioritized. Imaging-pathologic correlation when available will improve the understanding of early structural, functional, and molecular changes observed in vivo and may help identify novel therapeutic targets. Cross- modality image analyses and results of imaging genetics studies with ADNI, DIAN, and others will contribute to advances in early detection, mechanistic understanding, and optimize imaging as a dynamic biomarker to study therapeutic effects. Acquiring standardized state-of-the-art MRI and PET data for use by many investigators will increase research productivity and facilitate quantitative analyses. Integration with other cores will allow the IADRC to expand on these analyses by relating imaging biomarkers to neuropsychological measures, neuropathologic samples, genetic and other –omics markers. The NIC will continue to foster and support advanced imaging research through local, regional, and national/international collaborations. The NIC will advance AD imaging research to meet the goal of NAPA for preventing and effectively treating AD by 2025.

项目摘要 - 神经成像核心（NIC） IADRC的NIC将作为衰老和神经变性的区域和国家资源通过提供高级应用的访问和协作支持来研究社区临床和翻译研究中的神经影像学。 NIC在开发和在神经成像和成像遗传分析中实施尖端方案和技术，与NIA资助的倡议（例如ADNI，DIAN，ADGC等）合作，并提供培训神经影像和成像遗传学对各个层次和学科的科学家。在此应用程序中，NIC将追求以下具体目的：（1）支持IADRC，IU衰老研究中心的资助研究，以及目前使用或可能受益于先进神经影像学的相关计划；（2）提供标准化的，最先进的神经影像学获得和分析方案；（3）扩大跨学科区域神经科学研究使用先进的神经影像学工具研究疾病机制和神经退行性的治疗；（4）支持并与主要国家和国际广告相关的主要使用神经成像和遗传学方法的研究联盟；（5）提供跨学科教育基本和临床的AD和其他退化性疾病的神经影像和遗传学的机会从本科生到博士后研究员和教师的各个层面的科学家，以及为社区的神经影像学结果。与临床核心紧密合作的NIC将执行 ART多模式MRI（西门子Prisma 3T：高分辨率结构性，3D PCASL灌注，多体静止 - 基于状态和任务的fMRI，以及针对结构和功能连接的混合扩散和DTI 分析）对所有合格的IADRC参与者，以及淀粉样蛋白和/或Tau PET> 200个IADRC参与者。参与临床前或早期症状阶段的参与者（例如，主观认知能力下降或轻度认知损害），晚期广告以及来自痴呆症因果关系因果关系的家庭将是优先。成像病理学相关性在可用时将改善对早期结构的理解，在体内观察到的功能和分子变化，可能有助于鉴定新的治疗靶标。叉- 与ADNI，DIAN和其他人一起成像遗传学研究的模态图像分析和结果将有助于早期检测，机械理解和优化成像作为动态生物标志物的进步研究治疗作用。获取标准化的最先进的MRI和PET数据，以供许多研究人员将提高研究生产率并促进定量分析。与其他核心集成将允许IADRC通过将成像生物标志物与神经心理学联系起来扩展这些分析措施，神经病理样本，遗传和其他 - 组标志物。 NIC将继续促进通过本地，地区和国家/国际合作支持高级成像研究。 NIC 将推进AD成像研究，以达到NAPA的目标，以防止和有效地处理2025年的AD。